PTC Therapeutics, Inc. announced that the European Commission (EC) has granted marketing authorization to Evrysdi™ for the treatment of spinal muscular atrophy(SMA) in patients 2 months and older. The EC approval was based on two studies; 1) the efficacy results from the FIREFISH study in infants aged 2 to 7 months with symptomatic Type 1 SMA, and 2) the SUNFISH study in children and young adults with Type 2 or 3 SMA.
[PTC Therapeutics, Inc.]
0